Cericlamine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Overview of the antidepressant drug Cericlamine}} | |||
{{Drugbox | |||
| image = Cericlamine.svg | |||
| image_size = 200px | |||
| image_alt = Structural formula of Cericlamine | |||
}} | |||
'''Cericlamine''' is a pharmaceutical compound that was investigated for its potential use as an [[antidepressant]]. It belongs to the class of drugs known as [[selective serotonin reuptake inhibitors]] (SSRIs), which are commonly used in the treatment of [[depression]] and other mood disorders. | |||
Cericlamine | ==Pharmacology== | ||
Cericlamine functions primarily by inhibiting the reuptake of [[serotonin]], a neurotransmitter that plays a key role in mood regulation. By preventing the reabsorption of serotonin into the presynaptic neuron, cericlamine increases the availability of serotonin in the [[synaptic cleft]], thereby enhancing serotonergic neurotransmission. | |||
== | ==Mechanism of Action== | ||
[[File:Cericlamine.svg|thumb|right|Structural formula of Cericlamine]] | |||
The mechanism of action of cericlamine is similar to that of other SSRIs. It selectively binds to the serotonin transporter (SERT) on the presynaptic neuron, blocking the reuptake of serotonin. This leads to an increase in serotonin levels in the synaptic cleft, which is thought to contribute to its antidepressant effects. | |||
Cericlamine | ==Clinical Development== | ||
Cericlamine was developed and studied in clinical trials to assess its efficacy and safety as an antidepressant. However, it did not reach the market due to various factors, including the availability of other effective SSRIs and potential side effects observed during trials. | |||
== | ==Side Effects== | ||
As with other SSRIs, cericlamine was associated with a range of side effects. Common side effects included [[nausea]], [[headache]], [[insomnia]], and [[sexual dysfunction]]. These side effects are typical of SSRIs due to their action on serotonin levels in the brain. | |||
Cericlamine | ==Comparison with Other SSRIs== | ||
Cericlamine was compared to other SSRIs such as [[fluoxetine]], [[sertraline]], and [[paroxetine]] during its development. While it showed similar efficacy in increasing serotonin levels, its side effect profile and lack of significant advantages over existing medications limited its commercial development. | |||
== | ==Related pages== | ||
* [[Selective serotonin reuptake inhibitor]] | |||
* [[Antidepressant]] | |||
* [[Serotonin]] | |||
* [[Depression (mood disorder)]] | |||
* [[ | |||
* [[ | |||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category: | [[Category:Selective serotonin reuptake inhibitors]] | ||
Latest revision as of 03:31, 13 February 2025
Overview of the antidepressant drug Cericlamine
| Cericlamine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Cericlamine is a pharmaceutical compound that was investigated for its potential use as an antidepressant. It belongs to the class of drugs known as selective serotonin reuptake inhibitors (SSRIs), which are commonly used in the treatment of depression and other mood disorders.
Pharmacology[edit]
Cericlamine functions primarily by inhibiting the reuptake of serotonin, a neurotransmitter that plays a key role in mood regulation. By preventing the reabsorption of serotonin into the presynaptic neuron, cericlamine increases the availability of serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission.
Mechanism of Action[edit]
The mechanism of action of cericlamine is similar to that of other SSRIs. It selectively binds to the serotonin transporter (SERT) on the presynaptic neuron, blocking the reuptake of serotonin. This leads to an increase in serotonin levels in the synaptic cleft, which is thought to contribute to its antidepressant effects.
Clinical Development[edit]
Cericlamine was developed and studied in clinical trials to assess its efficacy and safety as an antidepressant. However, it did not reach the market due to various factors, including the availability of other effective SSRIs and potential side effects observed during trials.
Side Effects[edit]
As with other SSRIs, cericlamine was associated with a range of side effects. Common side effects included nausea, headache, insomnia, and sexual dysfunction. These side effects are typical of SSRIs due to their action on serotonin levels in the brain.
Comparison with Other SSRIs[edit]
Cericlamine was compared to other SSRIs such as fluoxetine, sertraline, and paroxetine during its development. While it showed similar efficacy in increasing serotonin levels, its side effect profile and lack of significant advantages over existing medications limited its commercial development.
